MediciNova (MNOV) publishes positive Phase 2 results for its asthma study, MN-221, in the...

|By:, SA News Editor

MediciNova (MNOV) publishes positive Phase 2 results for its asthma study, MN-221, in the Journal of Asthma. MN-221 is designed to treat acute asthmatic episodes through an intravenous infusion, which bypasses constricted airways to deliver the drug directly to the lungs. The tests showed a positive lung response without an accompanying increase in heart rate - which is a major concern - when the drugs were administered.